Sugi Predict

Sugi Predict / Compounds / SCHEMBL1233709

SCHEMBL1233709

SCHEMBL1233709

[CH2]CCc1cc(-c2ccccc2)no1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 2/20 0.64
▸ NPC1 O15118 6/20 0.57
▸ RAB9A P51151 6/20 0.57
▸ SMN1; SMN2 Q16637 5/20 0.57
▸ TDP1 Q9NUW8 3/20 0.57
▸ L3MBTL1 Q9Y468 3/20 0.57
▸ LMNA P02545 2/20 0.57
▸ MAPT P10636 2/20 0.51
▸ CYP11B1 P15538 3/20 0.50
▸ DRD2 P14416 3/20 0.50
▸ DRD4 P21917 3/20 0.50
▸ DRD3 P35462 3/20 0.50
▸ CYP11B2 P19099 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ MMP2 P08253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14058091 0.83 MEN1 (0.52) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL6027760 0.83 NOTUM (0.66) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL1233954 0.82 CYP2A6 (0.68) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL23881826 0.82 NOTUM (0.64) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL27864683 0.82 NOTUM (0.64) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL15603519 0.82 NOTUM (0.74) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL23881879 0.82 NOTUM (0.64) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL23881749 0.82 NOTUM (0.74) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL4120542 0.82 NOTUM (0.64) NOTUMNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL28680089 0.79 NOTUM (0.60) NOTUMNPC1RAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1696912-B1 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2016-05-11 — — EP claimed
US-9145410-B2 Pyrazolopyridines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-09-29 — — US claimed
US-20120121651-A1 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY 2012-05-17 — — US claimed
US-7879849-B2 such as 1-(2-Methylpropyl)-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine, used as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-02-01 — — US claimed
US-20090318435-A1 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY 2009-12-24 — — US claimed
EP-1696912-A4 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2009-06-03 — — EP claimed
EP-1863809-A2 PYRAZOLOPYRIDINES AND ANALOGS THEREOF Coley Pharmaceutical Group, Inc. (US) 2007-12-12 — — EP claimed
EP-1850849-A2 METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON Coley Pharmaceutical Group, Inc. (US) 2007-11-07 — — EP claimed
WO-2006107753-A2 PYRAZOLOPYRIDINES AND ANALOGS THEREOF COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-10-12 — — WO claimed
EP-1696912-A2 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2006-09-06 — — EP claimed
WO-2006091647-A2 METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 — — WO claimed
WO-2005079195-A2 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-09-01 — — WO claimed
EP-1696912-B1 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2016-05-11 — — EP disclosed
US-9145410-B2 Pyrazolopyridines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-09-29 — — US disclosed
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 — — US disclosed
US-20120121651-A1 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY 2012-05-17 — — US disclosed
EP-1696912-A2 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2006-09-06 — — EP disclosed
WO-2006091647-A2 METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 — — WO disclosed
US-20060100229-A1 Pyrazolopyridines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2006-05-11 — — US disclosed
WO-2005079195-A2 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100229-A1 Pyrazolopyridines and analogs thereof IL4, IL2, IL4I1 NOTUM 4152/4885NPC1 3412/4885RAB9A 1946/4885
US-20120121651-A1 PYRAZOLOPYRIDINES AND ANALOGS THEREOF IL4, IL4I1, IL2 NOTUM 3562/4885NPC1 3331/4885RAB9A 2019/4885
US-20090318435-A1 PYRAZOLOPYRIDINES AND ANALOGS THEREOF IL4, IL2, IL4I1 NOTUM 4152/4885NPC1 3412/4885RAB9A 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.